Novo Nordisk's Lead Fades, Eli Lilly Holds Course For Outsized Gains, Says Analyst

benzinga.com/analyst-stock-ratings/analyst-color/25/08/47164129/novo-nordisks-lead-fades-eli-lilly-holds-course-for-outsized-gains-says-analy

On Thursday, Eli Lilly and Co. (NYSE:LLY) said it will sharply increase the list price of its weight-loss and type 2 diabetes drug Mounjaro (tirzepatide) in the United Kingdom.
The moves underscore growing competition with Danish rival Novo Nordisk A/S (NYSE:NVO) in the lucrative obesity…

This story appeared on benzinga.com, 2025-08-15 17:54:23.
The Entire Business World on a Single Page. Free to Use →